PaxVax, Inc. Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine
Published: Sep 06, 2013
MENLO PARK, Calif.--(BUSINESS WIRE)--PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.
Help employers find you! Check out all the jobs and post your resume.